Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

NCT04727853 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG: irinotecan liposome injection

Sponsor

CSPC Ouyi Pharmaceutical Co., Ltd.